Skip to main content
. 2015 Apr 27;10(4):e0124601. doi: 10.1371/journal.pone.0124601

Fig 1. Overall survival (OS), disease-free survival (DFS) and locoregional control (LRC) rates for all patients undergoing postoperative chemoradiotherapy with capecitabine and concurrent intensity-modulated radiotherapy (IMRT)/three-dimensional conformal radiotherapy (3D-CRT).

Fig 1